Core Insights - Hongyuan Pharmaceutical (301246) invests nearly 70 million yuan annually in R&D and collaborates deeply with universities such as Fudan University and Wuhan University, establishing a comprehensive innovation system [1] - The company holds 65 patents, including 57 invention patents, and has received multiple provincial science and technology progress awards for its innovative processes [1] - In the pharmaceutical sector, Hongyuan has built a complete industrial chain covering nitroimidazole antibacterial drugs, becoming a major global supplier with leading market share in core products [1] - In the new energy sector, the company has developed a "rheological reverse reaction method for preparing lithium hexafluorophosphate" in collaboration with Wuhan University, achieving international advanced levels and becoming a supplier for BYD (002594) [1] - Hongyuan is advancing its "third-generation" lithium hexafluorophosphate technology and is scaling up a 6000-ton high-purity crystal project, which is expected to enhance its market share in the electrolyte sector upon production [1]